PharmaShots Weekly Snapshots ( October 30– November 03, 2023)

Share this

PharmaShots Weekly Snapshots ( October 30– November 03, 2023)

This week PharmaShots’ news was all about the updates on clinical trials, regulatory, pharma, M&A, MedTech, and DigiHealth. Check out our full report below:

The US FDA Approved Merck’s Keytruda with Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer 

Read More:Merck

Coherus and Junshi Bioscience's Loqtorzi (toripalimab-tpzi) Received the US FDA’s Approval to Treat Nasopharyngeal Carcinoma (NPC) 

Read More:Coherus and Junshi Bioscience

The US FDA Grants Santhera’s Agamree (vamorolone) Approval for the Treatment of Duchenne Muscular Dystrophy (DMD) 

Read More:More Santhera

Idorsia Pharmaceuticals Reports the NDA Submission of Daridorexant to the PMDA for the Treatment of Insomnia 

Read More:Idorsia Pharmaceuticals

BMS Receives EMA’s Validation of Opdivo (nivolumab) + Cisplatin-Based CT for 1L Treatment of Unresectable or Metastatic Urothelial Carcinoma 

Read More:BMS

Novartis Received The US FDA's Approval for Cosentyx to Treat Hidradenitis Suppurativa 

Read More:Novartis

The US FDA Approved Amgen's Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases 

Read More:Amgen

Abbott's Alinity M High Risk (HR) HPV assay for the Detection of HPV Infections has been approved by the US FDA 

Read More:Abbott

The US FDA has accepted to review the resubmitted NDA of Supernus' SPN-830 for the Treatment of Off Episodes in Parkinson’s Disease 

Read More:Supernus


GSK Reports Positive Results of P-III Study (RUBY) for Jemperli + CT in Primary Advanced or Recurrent Endometrial Cancer Patients 

Read More:GSK

Novartis’ Reports Results of Atrsentan in P-III Study for the Treatment of IgA Nephropathy 

Read More:Novartis

Otsuka Pharmaceutical Reports Results for Centanafadine in Two P-III Trials for the Treatment of ADHD 

Read More:Otsuka Pharmaceutical

Teva Pharmaceutical Reports P-III Results of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia 

Read More:Teva Pharmaceutical

T3D Therapeutics has announced promising outcomes from the P-II study (PIONEER) of T3D-959 in the treatment of Alzheimer's Disease 

Read More:T3D Therapeutics

Innate Pharma Presents P-II Study (TELLOMAK) Results of Lacutamab for the Treatment of Sézary Syndrome 

Read More:Innate Pharma

Roche Reports Positive Efficacy Results from the P-III Study (EMBARK) of Elevidys for Duchenne Muscular Dystrophy (DMD) 

Read More:Roche

Merck Reports Secondary Endpoint Results of Keytruda in P-III Trial for the Treatment of Renal Cell Carcinoma (RCC) 

Read More:Merck

Adaptimmune Reports Positive Data from the P-II Trial Assessing Lete-cel for the Treatment of Synovial Sarcoma And Myxoid/Round Cell Liposarcoma (MRCLS) 

Read More:Adaptimmune

UCB Publishes the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy in ‘Epilepsy & Behavior’ 

Read More:UCB


Henlius Brings Hansizhuang (serplulimab injection) to Europe and India Through an Exclusive Licensing Agreement with Accord Healthcare 

Read More:Henlius & Accord Healthcare 

Sosei Heptares Receives a Milestone Payment of $3.75M as a Part of its Multi-Target Agreement with Genentech 

Read More:Sosei Heptares & Genentech 

Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement for the Development of HRS-1167 and SHR-A1904 to Treat Cancer 

Read More:Merck KGaA and Hengrui Pharma

Zydus and Guardant Health will Co-Promote the Guardant360 portfolio which includes Guardant360 and Guardant360 TissueNext tests for advanced solid cancers in India and Nepal 

Read More:Zydus and Guardant Health

AstraZeneca Signs a Collaboration Agreement with Cellectis to Develop Novel Cell and Gene Therapies for Oncology and Immunology Indications 

Read More:AstraZeneca & Cellectis

Abcellera and Prelude Therapeutics Entered into a Partnership to Develop ADCs Therapies for the Treatment of Cancer 

Read More:Abcellera and Prelude Therapeutics

Aldeyra Therapeutics Signs an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease 

Read More:Aldeyra Therapeutics & AbbVie

GSK Enters into an Agreement with Janssen and Arrowhead for JNJ-3989 to Treat Chronic Hepatitis B 

Read More:GSK, Janssen and Arrowhead

Abbott Reports Trial Data for Esprit BTK Drug-Eluting Resorbable Scaffold to Treat Chronic Limb-Threatening Ischemia (CLTI) 

Read More:Abbott

Shorla Oncology Acquires Jylamvo form Therakind as a Therapy Targeting Oncology and Autoimmune Indications 

Read More:Shorla Oncology & Jylamvo

The collaboration marks the expansion between R1 RCM and Microsoft to develop and integrate Generative AI and Revenue Cycle Management Platform 

Read More:R1 RCM and Microsoft

Related Post: PharmaShots Weekly Snapshots (October 23–27, 2023)


Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions